AMED vs. CHE, BTSG, ADUS, AHCO, OPCH, IRTC, IDYA, TXG, SWTX, and XENE
Should you be buying Amedisys stock or one of its competitors? The main competitors of Amedisys include Chemed (CHE), BrightSpring Health Services (BTSG), Addus HomeCare (ADUS), AdaptHealth (AHCO), Option Care Health (OPCH), iRhythm Technologies (IRTC), IDEAYA Biosciences (IDYA), 10x Genomics (TXG), SpringWorks Therapeutics (SWTX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "medical" sector.
Chemed (NYSE:CHE) and Amedisys (NASDAQ:AMED) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.
In the previous week, Chemed had 6 more articles in the media than Amedisys. MarketBeat recorded 9 mentions for Chemed and 3 mentions for Amedisys. Chemed's average media sentiment score of 1.70 beat Amedisys' score of 1.11 indicating that Amedisys is being referred to more favorably in the news media.
Chemed has higher revenue and earnings than Amedisys. Amedisys is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.
Chemed has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
Chemed has a net margin of 12.36% compared to Chemed's net margin of -0.91%. Amedisys' return on equity of 30.52% beat Chemed's return on equity.
Chemed presently has a consensus target price of $681.00, suggesting a potential upside of 20.42%. Amedisys has a consensus target price of $100.80, suggesting a potential upside of 6.75%. Given Amedisys' stronger consensus rating and higher possible upside, equities research analysts clearly believe Chemed is more favorable than Amedisys.
95.9% of Chemed shares are owned by institutional investors. Comparatively, 94.4% of Amedisys shares are owned by institutional investors. 3.3% of Chemed shares are owned by insiders. Comparatively, 1.8% of Amedisys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Amedisys received 166 more outperform votes than Chemed when rated by MarketBeat users. However, 63.39% of users gave Chemed an outperform vote while only 58.93% of users gave Amedisys an outperform vote.
Summary
Chemed beats Amedisys on 15 of the 18 factors compared between the two stocks.
Get Amedisys News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amedisys Competitors List
Related Companies and Tools
